Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Revival Gold hits 3.43 g/t gold over 132 meters at Beartrack-Arnett project in Idaho

Revival Gold hits 3.43 g/t gold over 132 meters at Beartrack-Arnett project in Idaho

ReutersReuters2026/08/04 11:37
  • Revival Gold reported a high-grade intercept at its Beartrack-Arnett project in Idaho from hole BT26-255D.
  • BT26-255D hit 3.43 g/t gold over 131.7 meters, including 6.56 g/t over 42.5 meters.
  • The high-grade section included 11.58 g/t gold over 12.1 meters; true widths are estimated at 40% to 50% of drilled widths.
  • The 5,500-meter 2026 drill program targets expansion of high-grade underground sulphide resources at the Joss area, last drilled in 2022.
  • Joss hosts an inferred underground sulphide resource of 6,745,000 tonnes at 4.05 g/t gold for 877,000 ounces, outside the 2023 heap-leach PFS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revival Gold Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608040730NEWSFILECNPR____20260804_307782_1) on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage